Salem Investment Counselors’s Amylyx Pharmaceuticals AMLX Stock Holding History

Salem Investment Counselors’s Portfolio AMLX Stock Details AMLX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$988	Hold	55	–	–	﹤0.01%	1155
2026 Q1	$765	Buy	+55	New	+$774	﹤0.01%	1147
2025 Q4	–	Sell	-55	Closed	-$748	–	421
2025 Q3	$748	Hold	55	–	–	﹤0.01%	1142
2025 Q2	$353	Hold	55	–	–	﹤0.01%	1128
2025 Q1	$195	Hold	55	–	–	﹤0.01%	1183
2024 Q4	$208	Hold	55	–	–	﹤0.01%	1158
2024 Q3	$179	Hold	55	–	–	﹤0.01%	1166
2024 Q2	$105	Hold	55	–	–	﹤0.01%	1145
2024 Q1	$157	Hold	55	–	–	﹤0.01%	1147
2023 Q4	$810	Buy	+55	New	+$843	﹤0.01%	1035

Other funds holding AMLX

IGAM

iA Global Asset Management Quebec, Quebec, Canada $8.42B AUM 47.61% 1-Year Est. Return

ALPS Advisors Denver, Colorado $21.3B AUM 23.41% 1-Year Est. Return

MAP

Moody Aldrich Partners Marblehead, Massachusetts $557M AUM 122.79% 1-Year Est. Return

New York State Common Retirement Fund Albany, New York $79.3B AUM 43.63% 1-Year Est. Return

PFSRSONJ

Police & Firemen's Retirement System of New Jersey Trenton, New Jersey $13.3B AUM 45.46% 1-Year Est. Return

PCM

Parsons Capital Management Providence, Rhode Island $2.21B AUM 28.12% 1-Year Est. Return

PPWP

Premier Path Wealth Partners Madison, New Jersey $870M AUM 30% 1-Year Est. Return

CUAMC

China Universal Asset Management Company Shanghai, China $1.67B AUM 89% 1-Year Est. Return

PSP Research Newtown Square, Pennsylvania $188M AUM

VFA

Valeo Financial Advisors Carmel, Indiana $4.74B AUM 27.69% 1-Year Est. Return

Salem Investment Counselors's AMLX Position: Q2 2026 in Review

Salem Investment Counselors held its Amylyx Pharmaceuticals (AMLX) position steady in Q2 2026 at 55 shares worth $988. The position accounts for ﹤0.01% of the portfolio, ranked #1155.

Salem Investment Counselors first reported a position in AMLX in Q4 2023 and has held it in 10 quarters since. 23 funds tracked by Wall St. Rank hold AMLX as of Q2 2026.

Salem Investment Counselors held 55 shares of Amylyx Pharmaceuticals worth $988 as of Q2 2026.
Salem Investment Counselors left its Amylyx Pharmaceuticals share count unchanged in Q2 2026.
Amylyx Pharmaceuticals made up ﹤0.01% of Salem Investment Counselors's portfolio in Q2 2026, its #1155 holding.
Salem Investment Counselors first reported a position in Amylyx Pharmaceuticals in Q4 2023 and has held it in 10 quarters since.
23 funds tracked by Wall St. Rank held Amylyx Pharmaceuticals as of Q2 2026.

Based on Salem Investment Counselors's 13F filing for Q2 2026, filed 14 Jul 2026.